Johnson & Johnson's ICOTYDE Receives FDA Approval for Psoriasis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
- FDA Approval: Johnson & Johnson announced that its IL-23 receptor antagonist ICOTYDE has received FDA approval, becoming the first targeted oral peptide for moderate-to-severe plaque psoriasis in patients aged 12 and older weighing at least 40 kg, marking a significant breakthrough in dermatological treatments.
- Clinical Trial Results: ICOTYDE met all primary efficacy endpoints in four Phase 3 studies involving 2,500 patients, demonstrating a favorable safety profile, which enhances its competitive position in the market.
- Significant Efficacy: In head-to-head studies, approximately 70% of patients achieved clear or almost clear skin at Week 16, and 55% reached a Psoriasis Area and Severity Index (PASI) 90 response, showcasing ICOTYDE's notable advantages in treatment outcomes.
- Patient Convenience: ICOTYDE offers a unique treatment option in a once-daily oral form, combining skin clearance with a favorable safety profile, making it an easy addition to patients' routines and is expected to drive increased market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 238.110
Low
190.00
Averages
218.50
High
240.00
Current: 238.110
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Launches First IL-23R Targeted Oral Drug ICOTYDE
- FDA Approval: Johnson & Johnson's ICOTYDE™ (icotrokinra) has received FDA approval as the first targeted oral drug for the IL-23 receptor, specifically designed for patients with moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Clinical Trial Results: In four Phase 3 studies involving 2,500 patients, ICOTYDE met all primary efficacy endpoints, with approximately 70% of patients achieving clear or almost clear skin at Week 16, demonstrating substantial therapeutic effectiveness.
- Good Safety Profile: The incidence of adverse reactions for ICOTYDE was comparable to placebo at just 1.1%, with no new safety signals identified through Week 52, indicating its safety for long-term use.
- Patient Support Program: Johnson & Johnson has launched the ICOTYDE withMe patient support program, offering free resources and dedicated support to help patients navigate their treatment, thereby enhancing patient experience and adherence to therapy.
See More
Johnson & Johnson's Icotyde Approved by FDA for Plaque Psoriasis
- FDA Approval: Johnson & Johnson announced that its once-daily pill Icotyde, developed with Protagonist Therapeutics, has received FDA approval as a treatment for moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Successful Clinical Trials: Icotyde demonstrated strong efficacy in J&J's pivotal ICONIC clinical development program, achieving primary efficacy endpoints with a favorable safety profile across four Phase 3 studies involving 2,500 patients, enhancing its competitive position in the market.
- Significant Market Need: Plaque psoriasis affects nearly 8 million Americans and 125 million people globally, with about 25% suffering from moderate-to-severe cases, and Icotyde offers an innovative treatment option for patients currently relying on topical therapies, addressing a critical market demand.
- Milestone Payments and Royalties: Protagonist Therapeutics announced that the FDA approval triggers a $50 million milestone payment and will receive 6%-10% royalties on Icotyde sales, along with potential future milestone payments of up to $580 million, significantly improving its financial outlook.
See More
Johnson & Johnson's ICOTYDE Receives FDA Approval for Psoriasis Treatment
- FDA Approval: Johnson & Johnson announced that its IL-23 receptor antagonist ICOTYDE has received FDA approval, becoming the first targeted oral peptide for moderate-to-severe plaque psoriasis in patients aged 12 and older weighing at least 40 kg, marking a significant breakthrough in dermatological treatments.
- Clinical Trial Results: ICOTYDE met all primary efficacy endpoints in four Phase 3 studies involving 2,500 patients, demonstrating a favorable safety profile, which enhances its competitive position in the market.
- Significant Efficacy: In head-to-head studies, approximately 70% of patients achieved clear or almost clear skin at Week 16, and 55% reached a Psoriasis Area and Severity Index (PASI) 90 response, showcasing ICOTYDE's notable advantages in treatment outcomes.
- Patient Convenience: ICOTYDE offers a unique treatment option in a once-daily oral form, combining skin clearance with a favorable safety profile, making it an easy addition to patients' routines and is expected to drive increased market demand.
See More
Johnson & Johnson Launches First IL-23R Targeted Oral Drug for Psoriasis
- FDA Approval: Johnson & Johnson's ICOTYDE™ (icotrokinra) has received FDA approval as the first targeted oral drug for IL-23 receptors, specifically designed for patients with moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Clinical Trial Results: In four Phase 3 studies involving 2,500 patients, ICOTYDE met all primary efficacy endpoints, with approximately 70% of patients achieving clear or almost clear skin at Week 16, demonstrating substantial therapeutic effectiveness.
- Favorable Safety Profile: The incidence of adverse reactions in ICOTYDE-treated patients was comparable to placebo at just 1.1%, with no new safety signals identified through Week 52, ensuring patient safety during treatment.
- Patient Support Program: Johnson & Johnson has launched the ICOTYDE withMe patient support program, offering free resources and dedicated support, including cost assistance and a dedicated Nurse Guide, aimed at enhancing patient experience and adherence to treatment.
See More
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
Johnson & Johnson Launches First IL-23R Targeted Oral Drug ICOTYDE
- FDA Approval: Johnson & Johnson's ICOTYDE™ (icotrokinra) has received FDA approval as the first targeted oral drug for the IL-23 receptor, specifically designed for patients with moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Clinical Trial Results: In four Phase 3 studies involving 2,500 patients, ICOTYDE met all primary efficacy endpoints, with approximately 70% of patients achieving clear or almost clear skin at Week 16, demonstrating substantial therapeutic effectiveness.
- Good Safety Profile: The incidence of adverse reactions for ICOTYDE was comparable to placebo at just 1.1%, with no new safety signals identified through Week 52, indicating its safety for long-term use.
- Patient Support Program: Johnson & Johnson has launched the ICOTYDE withMe patient support program, offering free resources and dedicated support to help patients navigate their treatment, thereby enhancing patient experience and adherence to therapy.
See More
Johnson & Johnson's Icotyde Approved by FDA for Plaque Psoriasis
- FDA Approval: Johnson & Johnson announced that its once-daily pill Icotyde, developed with Protagonist Therapeutics, has received FDA approval as a treatment for moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Successful Clinical Trials: Icotyde demonstrated strong efficacy in J&J's pivotal ICONIC clinical development program, achieving primary efficacy endpoints with a favorable safety profile across four Phase 3 studies involving 2,500 patients, enhancing its competitive position in the market.
- Significant Market Need: Plaque psoriasis affects nearly 8 million Americans and 125 million people globally, with about 25% suffering from moderate-to-severe cases, and Icotyde offers an innovative treatment option for patients currently relying on topical therapies, addressing a critical market demand.
- Milestone Payments and Royalties: Protagonist Therapeutics announced that the FDA approval triggers a $50 million milestone payment and will receive 6%-10% royalties on Icotyde sales, along with potential future milestone payments of up to $580 million, significantly improving its financial outlook.
See More
Johnson & Johnson's ICOTYDE Receives FDA Approval for Psoriasis Treatment
- FDA Approval: Johnson & Johnson announced that its IL-23 receptor antagonist ICOTYDE has received FDA approval, becoming the first targeted oral peptide for moderate-to-severe plaque psoriasis in patients aged 12 and older weighing at least 40 kg, marking a significant breakthrough in dermatological treatments.
- Clinical Trial Results: ICOTYDE met all primary efficacy endpoints in four Phase 3 studies involving 2,500 patients, demonstrating a favorable safety profile, which enhances its competitive position in the market.
- Significant Efficacy: In head-to-head studies, approximately 70% of patients achieved clear or almost clear skin at Week 16, and 55% reached a Psoriasis Area and Severity Index (PASI) 90 response, showcasing ICOTYDE's notable advantages in treatment outcomes.
- Patient Convenience: ICOTYDE offers a unique treatment option in a once-daily oral form, combining skin clearance with a favorable safety profile, making it an easy addition to patients' routines and is expected to drive increased market demand.
See More
Johnson & Johnson Launches First IL-23R Targeted Oral Drug for Psoriasis
- FDA Approval: Johnson & Johnson's ICOTYDE™ (icotrokinra) has received FDA approval as the first targeted oral drug for IL-23 receptors, specifically designed for patients with moderate-to-severe plaque psoriasis, marking a significant breakthrough in treatment options.
- Clinical Trial Results: In four Phase 3 studies involving 2,500 patients, ICOTYDE met all primary efficacy endpoints, with approximately 70% of patients achieving clear or almost clear skin at Week 16, demonstrating substantial therapeutic effectiveness.
- Favorable Safety Profile: The incidence of adverse reactions in ICOTYDE-treated patients was comparable to placebo at just 1.1%, with no new safety signals identified through Week 52, ensuring patient safety during treatment.
- Patient Support Program: Johnson & Johnson has launched the ICOTYDE withMe patient support program, offering free resources and dedicated support, including cost assistance and a dedicated Nurse Guide, aimed at enhancing patient experience and adherence to treatment.
See More
Investment Opportunities in Healthcare Sector
- Robotic Surgery Market Potential: Intuitive Surgical's da Vinci system leads the robotic-assisted surgery market, with an installed base of 11,106 units by 2025, reflecting a 12% year-over-year growth, indicating significant growth potential in this underpenetrated market, allowing for recurring revenue through disposable instruments and accessories sales.
- Innovation-Driven Growth: Intuitive Surgical plans to continue launching newer versions of the da Vinci system, and with increasing procedure volumes and label expansions, sales growth is expected to accelerate, despite competition from giants like Medtronic and Johnson & Johnson; the company's strong technological moat and flexible pricing power will help it overcome challenges.
- HCA's Network Advantage: HCA Healthcare operates a diversified network of healthcare facilities across the U.S., benefiting from long-term trends such as an aging population and rising demand for medical services, with sustained market share growth over the past 15 years, showcasing its strong adaptability in a competitive landscape.
- Investment in Technology and Relationships: HCA Healthcare improves patient outcomes through investments in cutting-edge medical technology and has built deep relationships with both government and private payers, creating a hard-to-replicate ecosystem; despite risks from policy changes, its diversified revenue sources suggest a positive long-term outlook.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
